Bone mineral density in children and adolescents with neurofibromatosis type 1. - Wikidata - awgldk - TriplyDB

Bone mineral density in children and adolescents with neurofibromatosis type 1.

Bone mineral density in children and adolescents with neurofibromatosis type 1.

http://www.wikidata.org/entity/Q35659149

about

The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1 Ras dependent paracrine secretion of osteopontin by Nf1+/- osteoblasts promote osteoclast activation in a neurofibromatosis type I murine model.Optimizing biologically targeted clinical trials for neurofibromatosis.Neurofibromatosis: chronological history and current issues.Generalized metabolic bone disease in Neurofibromatosis type I Statins, bone, and neurofibromatosis type 1 Tibial geometry in individuals with neurofibromatosis type 1 without anterolateral bowing of the lower leg using peripheral quantitative computed tomography.Nf1 Haploinsufficiency Alters Myeloid Lineage Commitment and Function, Leading to Deranged Skeletal Homeostasis.Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.Bone mineral density in children and young adults with neurofibromatosis type 1 Decreased bone mineralization in children with Noonan syndrome: another consequence of dysregulated RAS MAPKinase pathway?Skeletal manifestations in pediatric and adult patients with Niemann Pick disease type B.Dystrophic spinal deformities in a neurofibromatosis type 1 murine model.FGFR1 signaling in hypertrophic chondrocytes is attenuated by the Ras-GAP neurofibromin during endochondral bone formation.Motor proficiency in children with neurofibromatosis type 1 Evidence of increased bone resorption in neurofibromatosis type 1 using urinary pyridinium crosslink analysis Bone resorption in syndromes of the Ras/MAPK pathway.Pediatric 25-hydroxyvitamin D concentrations in neurofibromatosis type 1 c-Fms signaling mediates neurofibromatosis Type-1 osteoclast gain-in-functions.How does the Schwann cell lineage form tumors in NF1?The musculoskeletal phenotype of the RASopathies.Massive Soft Tissue Neurofibroma (Elephantiasis Neuromatosa): Case Report and Review of Literature.Aberrant Myeloid Differentiation Contributes to the Development of Osteoporosis in Neurofibromatosis Type 1.Does pamidronate enhance the osteogenesis in mesenchymal stem cells derived from fibrous hamartoma in congenital pseudarthrosis of the tibia?Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.Successful treatment of congenital pseudarthrosis of the tibia: still a challenge.A controlled register-based study of 460 neurofibromatosis 1 patients: increased fracture risk in children and adults over 41 years of age.Neurofibromatosis 1-related osteopenia often progresses to osteoporosis in 12 years.Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model.The role of motor proficiency in bone health in genetic syndromes.Constitutional bone impairment in Noonan syndrome.The generalized bone phenotype in children with neurofibromatosis 1: a sibling matched case-control study.Multiple increased osteoclast functions in individuals with neurofibromatosis type 1.Neurofibromatosis: part 2--clinical management.Hyperactivation of mTOR critically regulates abnormal osteoclastogenesis in neurofibromatosis Type 1.Early primary tooth eruption in neurofibromatosis 1 individuals Increased dental caries in people with neurofibromatosis 1

P2860

Q27319893-48DD048C-760F-4093-8D4B-4AF3C3095B49 Q30375214-2AFD2979-BABF-41BD-87D8-3BC5D032585B Q30438898-8FDC39D3-4D25-49E3-A0CF-EB57F7E7C3F6 Q30449267-CDFFFB67-B7B3-47E0-995C-346F319FFFB5 Q30841192-C9EFA521-6415-4758-BD33-EF57A93C2519 Q33356748-2F5DC36E-5D93-4227-A628-035E17089C6A Q33396860-9B74CEC4-1A33-4E55-BEAE-48643CB0460F Q33718764-AFADB737-6C68-4402-A4B4-58E3BF539D92 Q34020971-62960D28-A1C6-4CF7-9B89-24248425ABE5 Q34045437-E0CF8120-45F7-4579-AF93-537EF9A7C744 Q34253927-97B97ED6-B637-490E-B8B1-97B072F92AD5 Q34311272-AFDAA115-19C2-4324-81EA-626E4D86DE89 Q35191542-7EC705E4-19EA-4D3F-8F7C-98DA09CCF798 Q35253119-126A8A04-8DFC-4A97-8DF9-DA18E373891F Q35605308-F7AD160B-9F39-4E0A-AE5E-AD78F3FF15BA Q35605316-39CF089A-CA97-425A-A18A-5457B881BA60 Q35635487-2E22C5C5-F52C-4F2D-92BB-548B79253DC4 Q35635492-EF8B61D6-787B-4130-A130-71C6EAF0426B Q36380904-D2FE2F8F-5151-457E-A46C-003FD78789F2 Q37120518-6DA7C058-C417-40FA-A8B7-72140375B38E Q37865455-06712FCD-9531-45BF-BC58-0091F93814EE Q38360990-8DF9A971-F025-4DDC-B21C-DA121734BFE2 Q38757104-DAF52375-5F19-4062-91DC-E15C51C57CB0 Q41891999-3395FEE5-6206-4638-A53D-EBF9BFE7FD86 Q41917599-2BB3C0B2-07A5-47C2-A763-35BEA8860331 Q42918689-285D1B13-7305-41E7-81B8-612D47F7E0DD Q43411814-33AA29F5-8C31-4E28-B112-83F9B235639F Q45187619-86B3E50C-491A-4D10-8CC4-D5BEAA39DEE8 Q45846222-F8D950A8-1CEF-42F3-9D3B-F64377F05D81 Q46798931-3568B8A1-37DF-4FCF-82A9-D7B43BEF710C Q51891075-7D140B4A-6E88-4451-A15D-FBF7AD7E76A2 Q52905410-3D01BA78-6EA7-46A9-9BA6-4965BE0970B3 Q53107807-6B536847-1823-45A3-BC24-01D5FCCC4097 Q53256313-F06DFAAC-D909-4A56-BE27-01903949D32B Q53464959-2FB87014-6D93-4DEB-8249-DDE079D52E08 Q54574990-DD31059C-6081-409F-BD35-CCC7EA7AB521 Q57386683-59EF2887-F9C7-4623-96DD-B962D12E5A89 Q57386685-65BCBEE2-6B37-44F4-95B5-E95AEFFF18E0

P2860

Bone mineral density in children and adolescents with neurofibromatosis type 1.

http://www.wikidata.org/entity/Q35659149

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Bone mineral density in children and adolescents with neurofibromatosis type 1.

@ast

Bone mineral density in children and adolescents with neurofibromatosis type 1.

@en

type

label

Bone mineral density in children and adolescents with neurofibromatosis type 1.

@ast

Bone mineral density in children and adolescents with neurofibromatosis type 1.

@en

prefLabel

Bone mineral density in children and adolescents with neurofibromatosis type 1.

@ast

Bone mineral density in children and adolescents with neurofibromatosis type 1.

@en

P1433

Q35659149-F288BBE5-E467-4086-8B52-BEE3B2A83963

P1476

Q35659149-0306502A-DF4B-48C3-9D68-35D0A2FA225F

P2093

Q35659149-364D1433-333D-4640-9038-0ABC0D428368

Q35659149-36C742E0-8D01-4FE3-B634-14DC72BAC421

Q35659149-6F1D7DD9-F93F-4880-A327-8C16623ACAE0

Q35659149-8FAF115F-3EEC-4778-BBAC-F53B04FB061D

Q35659149-9DD5C7CB-5281-4DCF-8C26-238F1D1EECA6

Q35659149-ACF02AD2-52D9-4F1C-80CF-B0F083EC34C5

Q35659149-B58A35C5-0B76-4BFF-9967-3BB977C04E5B

Q35659149-C76283CC-3F24-462D-AD18-549172D086E9

P2860

Q35659149-00125579-2545-4898-AB7A-3984746611CE

Q35659149-033B4C9D-31B5-4E19-8D25-22FB3BA4FCFF

Q35659149-16E7F761-82D2-44A1-99B2-F8EAAA7A26B5

Q35659149-1FBE3F25-AECA-4078-AE5F-9ECACD9BB0B4

Q35659149-202ED327-8375-49F9-B51B-EE06013F114A

Q35659149-25B04422-8250-4FF0-A2FE-AB0AA80BCE32

Q35659149-40FA72D7-9693-4C3B-B3CF-47EC308DA959

Q35659149-4986B441-6C6C-4B97-A114-2D5FA501678C

Q35659149-498F4292-EDFC-4EB6-918D-8F477C43A10D

Q35659149-4F7B2096-02F5-4457-B1AF-C1FA4CCD3B2D

P304

Q35659149-522DC737-8D0E-4F19-8199-DA5660C71BDB

P31

Q35659149-BCF75E17-2DCF-43BA-9129-37EB482F2936

P356

Q35659149-09AE190A-8BF4-4189-B25C-FFE4E7A3EFA4

P407

Q35659149-6130776C-2EB0-4C95-BC9C-4F049C92E5E3

P433

Q35659149-94C727E9-416E-4CA3-B4C0-7E332190D8AE

P478

Q35659149-35FD6B97-4274-4CF7-ACA2-B1B2A2B33E17

P577

Q35659149-2068777A-7357-472F-AAFB-EFF26067C658

P5875

Q35659149-B1D17E4A-0BF2-4A22-B2B6-DCA9F1334FB2

P698

Q35659149-FFB53C73-1F58-44B1-B7E4-A160D41B7488

P921

Q35659149-FA9C9CC0-1C5E-49A5-9730-FA9BFBDFD087

P932

Q35659149-6D4CD203-3D82-4CA9-A461-C088BB3BBF09

P356

J.JPEDS.2006.10.048

P1433

The Journal of Pediatrics

P1476

Bone mineral density in children and adolescents with neurofibromatosis type 1.

@en

P2093

Bukhosi Dube

http://www.w3.org/2001/XMLSchema#string

David A Stevenson

http://www.w3.org/2001/XMLSchema#string

David H Viskochil

http://www.w3.org/2001/XMLSchema#string

Hillarie Slater

http://www.w3.org/2001/XMLSchema#string

John C Carey

http://www.w3.org/2001/XMLSchema#string

Laurie J Moyer-Mileur

http://www.w3.org/2001/XMLSchema#string

Mary Murray

http://www.w3.org/2001/XMLSchema#string

Xiaoming Sheng

http://www.w3.org/2001/XMLSchema#string

P2860

Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding site in the collagen type I alpha 1 gene

Z score prediction model for assessment of bone mineral content in pediatric diseases.

Gene polymorphisms, bone mineral density and bone mineral content in young children: the Iowa Bone Development Study.

Polymorphisms in the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with variation in vertebral bone mass, vertebral bone size, and stature in whites.

Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body.

Clinical and anthropometric correlates of bone mineral acquisition in healthy adolescent girls.

Neurofibromatosis in children: the role of the orthopaedist.

Compendium of physical activities: classification of energy costs of human physical activities.

The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2.

Genetics of neurofibromatosis 1 and the NF1 gene.

P304

83-88

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JPEDS.2006.10.048

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

150

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6611192

http://www.w3.org/2001/XMLSchema#string

P698

17188620

http://www.w3.org/2001/XMLSchema#string

P921

P932

1808316

http://www.w3.org/2001/XMLSchema#string